ImmunoPrecise Antibodies Ltd. Files 6-K Report
Ticker: HYFT · Form: 6-K · Filed: Jan 17, 2025 · CIK: 1715925
Sentiment: neutral
Topics: regulatory-filing, press-release
TL;DR
IPA files 6-K with press release on Jan 17, 2025.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on January 17, 2025, reporting on its activities for the month of January 2025. The filing includes a press release dated January 17, 2025, as Exhibit 99.1. The company is incorporated in British Columbia and its principal executive office is located in Victoria.
Why It Matters
This filing provides an update on the company's regulatory disclosures and includes a press release, which may contain important business or financial information for investors.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to submit a press release and does not appear to contain significant new financial or operational disclosures.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Filer of the report
- January 17, 2025 (date) — Date of the press release and filing
- Jennifer Bath (person) — Signatory for the company
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public pursuant to the laws of their home country or that they have filed or will file with a stock exchange.
What is included as an exhibit in this 6-K filing?
Exhibit 99.1 is a Press Release dated January 17, 2025.
What is the principal executive office address for ImmunoPrecise Antibodies Ltd.?
The principal executive office is located at 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
Which form does ImmunoPrecise Antibodies Ltd. file annual reports under?
The registrant indicates it files annual reports under Form 20-F.
Who signed the report on behalf of ImmunoPrecise Antibodies Ltd.?
The report was signed by Jennifer Bath.
Filing Stats: 145 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2025-01-17 11:30:03
Filing Documents
- press_release_jan_17_202.htm (6-K) — 22KB
- ipa-ex99_1.htm (EX-99.1) — 16KB
- 0000950170-25-006517.txt ( ) — 39KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: January 17, 2025 By: /s/ Jennifer Bath Name: Jennifer Bath Title: President and Chief Executive Officer